Clinical Trials on Adenocarcinoma of the Prostate Stage II

Total 1534 results

Case Comprehensive Cancer Center

Terminated

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

Adenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage III

United States
Dana-Farber Cancer Institute

Completed

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Prostate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage III

United States
National Cancer Institute (NCI)

Completed

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
University of Washington
National Cancer Institute (NCI)

Completed

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer (RAD1)

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
John P. Fruehauf
Sanofi

Withdrawn

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate (2007-5904)

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate
National Cancer Institute (NCI)

Completed

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Completed

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Genistein in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
Virginia Commonwealth University

Completed

Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Puerto Rico
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer

Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

Stage IIB Prostate Cancer | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
University of California, Irvine

Completed

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
Genentech, Inc.

Completed

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma
National Cancer Institute (NCI)

Completed

Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Recurrent Prostate Cancer | Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

High-Dose Stereotactic Radiation for Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Case Comprehensive Cancer Center

Completed

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
John P. Fruehauf
Sanofi

Terminated

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Recurrent Prostate Cancer | Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer

Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of California, San Francisco

Completed

Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7

United States
Andrei Iagaru
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Switzerland
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage III Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7

United States
University of Washington
National Cancer Institute (NCI); Prostate Cancer Foundation

Terminated

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Mayo Clinic

Completed

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Burzynski Research Institute

Withdrawn

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Pharmavite LLC; Seafood Industry Research Fund

Active, not recruiting

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Adenocarcinoma of the Gastroesophageal Junction | Stage II Gastric Cancer | Stage III Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Stomach | Adenocarcinoma of the Esophagus | Stage III Esophageal Cancer | Stage II Esophageal Cancer

United States
National Cancer Institute (NCI)

Terminated

Perifosine in Treating Patients With Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
University of Colorado, Denver

Completed

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

Bone Metastases | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Soft Tissue Metastases

United States
University of Wisconsin, Madison

Active, not recruiting

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States

Clinical Trials on Adenocarcinoma of the Prostate Stage II

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations